Key Highlights
- Shares fell 5.09% in pre-market trading to $38.63, down from a prior close of $40.70
- Second quarter 2026 Revenue was $70.7 million, up 60% sequentially and 11% year over year
- Net loss widened to $17.3 million from Net Income of $5.0 million in the prior-year period
- Reiterated full-year 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA
- VEVYE quarterly revenue reached $29.4 million, up approximately 58% year over year
- Announced the Acquisition of TYRVAYA, expected to close in the second half of 2026
- Cash and cash equivalents were $83.9 million as of June 30, 2026
Shares Fall on Wider Net Loss Despite Revenue Growth
Harrow (NASDAQ:HROW) shares were trading at $38.63 in pre-market activity on August 11, 2026, down 5.09% from the prior close of $40.70. The decline followed second quarter 2026 results in which revenue of $70.7 million grew 60% sequentially and 11% year over year, but the company swung to a net loss of $17.3 million, or $0.46 per share, compared to net income of $5.0 million, or $0.14 per share, a year earlier.
Adjusted EBITDA came in at negative $1.2 million for the quarter, down from positive $17.0 million in the prior-year period, driven by higher selling, general, and administrative expenses and increased Research and Development spending. Despite the swing to a net loss, the company reiterated its full-year 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA.
What Harrow Does
Harrow is a Nashville, Tennessee-based leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products addressing conditions affecting both the front and back of the eye, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina conditions. The company's branded pharmaceuticals portfolio includes FDA-approved products such as IHEEZO, VEVYE, TRIESENCE, and MAXITROL.
Chairman and Chief Executive Officer Mark L. Baum said the company spent the first half of 2026 building Demand and positioning the Business to achieve its 2026 and 2027 financial objectives, with the second half focused on converting that demand into accelerating revenue growth and profitability.
Product Portfolio Momentum
VEVYE delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with total prescriptions increasing approximately 21% sequentially, ahead of branded dry eye disease market growth of 14%, and branded Market Share expanding to 14.6%, nearly doubling from 7.8% a year ago. The product also secured expanded formulary coverage with a top-three national commercial pharmacy benefit manager effective August 1, 2026.
IHEEZO delivered quarterly revenue of $15.6 million and achieved record quarterly unit demand of 65,477 units, up 44% sequentially and 34% year over year, despite the April 1, 2026 loss of pass-through reimbursement status for cataract surgery. TRIESENCE also delivered record quarterly unit demand of 14,529 units, up 39% sequentially and 162% year over year. The company also announced the acquisition of TYRVAYA, expected to close in the second half of 2026 and contribute more than $30 million in revenue in 2027.
Balance Sheet and Pipeline Updates
Harrow ended the quarter with $83.9 million in cash and cash equivalents, up from $72.9 million at the end of 2025, with total Assets of $416.8 million and loans payable of $292.4 million. The company successfully launched BYOOVIZ, a biosimilar to LUCENTIS, in July 2026, marking its entry into the U.S. retinal anti-VEGF market.
On the regulatory front, the FDA granted Harrow a pre-NDA meeting for its G-MELT program, while topline data from the QUELL trial evaluating IHEEZO in patients undergoing intravitreal injections are expected in the fourth quarter of 2026. The company's Phase 3 trial for TRIESENCE in ocular inflammation and pain following cataract surgery is on track to fully enroll in 2026, with topline data expected in early 2027.
Conclusion
Harrow's pre-market decline reflects investor focus on the swing to a net loss and negative adjusted EBITDA for the quarter, even as revenue grew meaningfully and the company reiterated its full-year guidance. With VEVYE, IHEEZO, and TRIESENCE all showing strong underlying demand growth and the TYRVAYA acquisition expected to add further revenue in 2027, management's confidence in accelerating growth and profitability in the second half of 2026 will be tested against the market's near-term focus on the quarter's bottom-line results.






Please wait processing your request...